Zolevi Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Levetiracetam

Indications/Uses

Partial onset seizures w/ or w/o secondary generalisation in adults & adolescents 16 yr w/ newly diagnosed epilepsy. Adjunctive therapy in the treatment of partial onset seizures w/ or w/o secondary generalisation in adults, adolescents, childn & infants from 1 mth w/ epilepsy; myoclonic seizures in adults & juvenile myoclonic seizures in adolescents from 12 yrs; primary generalised tonic-clonic seizures in adults & idiopathic generalised epilepsy in adolescents from 12 yr.

Click to view Zolevi detailed prescribing information

Dosage/Direction for Use

Monotherapy for adult & adolescent from 16 yr Initially 250 mg bid, increased to 500 mg bid after 2 wk, dose can be further increased by 250 mg bid every 2 wk depending on the clinical response. Max: 1,500 mg bid. Add-on therapy for adult (≥18 yrs) & adolescent (12-17 yrs) weighing ≥50 kg Initially 500 mg bid in the 1st day of treatment. Dose may be increased to 1,500 mg bid. Dose may be increase or decrease to 500 mg bid every 2-4 wk. Childn & adolescent ≥50 kg Adult dose, 25 kg 250 mg bid. Max: 750 mg bid.

Click to view Zolevi detailed prescribing information

Overdosage

View Zolevi overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food.

Contraindications

Hypersensitivity to levetiracetam or other pyrrolidone derivatives.

Click to view Zolevi detailed prescribing information

Special Precautions

Neutropenia, agranulocytosis, leukopenia, thrombocytopenia & pancytopenia. Increased risk of suicidal thoughts & behaviour; monitor for signs of depression &/or suicidal ideation & behaviour. Renal impairment. Acute kidney injury. Minor or moderate influence on the ability to drive & machines. Pregnancy & lactation. Not adapted for use in infants & childn <6 yr.

Click to view Zolevi detailed prescribing information

Use In Pregnancy & Lactation

Click to view Zolevi detailed prescribing information

Adverse Reactions

Nasopharyngitis, somnolence, headache, fatigue & dizziness. Anorexia; depression, hostility/aggression, anxiety, insomnia, nervousness/irritability; convulsion, balance disorder, lethargy, tremor; vertigo; cough; abdominal pain, diarrhoea, dyspepsia, vomiting, nausea; rash.

Click to view Zolevi detailed prescribing information

Drug Interactions

Decrease MTX clearance resulting in increased/prolonged blood MTX conc to potentially toxic levels. Decreased efficacy w/ macrogol.

Click to view Zolevi detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Zolevi detailed prescribing information

Storage

View Zolevi storage conditions for details to ensure optimal shelf-life.

Description

View Zolevi description for details of the chemical structure and excipients (inactive components).

Action

View Zolevi mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Anticonvulsants

ATC Classification

N03AX14 - levetiracetam ; Belongs to the class of other antiepileptics.

Regulatory Classification

Presentation/Packing

Form

Zolevi FC tab 1 g

Packing/Price

60's (P3,720/box)

Form

Zolevi FC tab 250 mg

Packing/Price

60's (P1,320/box)

Form

Zolevi FC tab 500 mg

Packing/Price

60's (P1,800/box)

Zolevi

levetiracetam

Manufacturer:

Lek Pharma

Distributor:

Natrapharm